A SELF NANOEMULSIFYING DRUG DELIVERY SYSTEM FOR IMPROVEMENT IN ORAL BIOAVAILABILITY OF NIMODIPINE: IN-VIVO EVALUATION

The current research involves the study of a Nimodipine self-nanoemulsifying drug delivery system (SNEDDS) with improved bioavailability and solubility. Fifteen formulations of Nimodipine SNEDDS were prepared prior to evaluation of particle size, emulsification time, percentage drug release, percentage transmittance, thermodynamic stability and in-vitro drug release. The formulation F13 was chosen as an optimized formulation with the composition of Peceol, Transcutol P, and PEG 400. The optimized Nimodipine SNEDDS formulation (F13) subjected to drug-excipient compatibility studies by FTIR. The particle size of the optimized Nimodipine SNEDDS formulation was 25.9 nm, PDI is 0.382, and zeta potential -12.7 mV that are optimal for the stability of the emulsion. SEM studies of Nimodipine SNEDDS indicated spherical shape and uniform particle distribution. Furthermore, Pharmacokinetic studies were conducted in rats, and plasma drug concentration-time curves revealed that significant increase in optimized SNEDDS concentration compares to that of a drug. Hence a potential SNEDDS formulation of Nimodipine developed with increased dissolution rate and solubility and bioavailability.